Investing

5 All-New Stocks to Buy Trading Under $10 With Gigantic Upside Potential

CymaBay Therapeutics

This stock was crushed after clinical data disappointed during the week, but Citigroup keeps a Buy rating on the shares. CymaBay Therapeutics Inc. (NASDAQ: CBAY) is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025, which aims to treat lipid and liver diseases, and Arhalofenate, which intends to reduce gout flares and serum uric acid.

Last Tuesday, CymaBay announced top-line 12-week data from a Phase 2b study of Seladelpar in patients suffering from nonalcoholic steatohepatitis (NASH). The results were mixed. According to the company, reductions in liver fat, a key marker of success in NASH therapies, were not significantly better in patients who received the drug than in patients who received a placebo. Still, the company said that patients who received the drug did demonstrate reductions in liver injury.

CymaBay had performed well this year, rising 40.9% before last Tuesday’s rout erased those gains, and then some. The lead drug in the company’s pipeline, Seladelpar, is designed to treat autoimmune liver diseases.

Citigroup dropped the $22 price target to $12, and the consensus target of $21.64 also could be coming down. Shares retreated last week from nearly $12 to less than $7.

Encana

This stock has pulled back sharply and is offering an outstanding entry point. Encana Corp. (NYSE: ECA) is an energy producer focused on developing its multibasin portfolio of natural gas, oil and natural gas liquids (NGLs) producing plays. Its operations also include the marketing of natural gas, oil and NGLs. All of its reserves and production are located in North America.

Its Canadian Operations segment includes the exploration for and development and production of natural gas oil and NGLs and other related activities within Canada. This includes Montney in northeast British Columbia and northwest Alberta and Duvernay in west central Alberta. The USA Operations segment includes the exploration for and development and production of natural gas, oil and NGLs and other related activities within the United States.

Merrill Lynch analysts remain positive on the company and have an $11 price target. The consensus is nearby at $10.54, but the shares were last seen still below $5.

TiVo

This company’s name actually became a verb years ago when people referred to recording TV shows. TiVo Corp. (NASDAQ: TIVO) provides entertainment technology, software and services. It operates through two segments.

The Intellectual Property Licensing segment consists of International Patent Group patent licensing to third-party guide developers such as multichannel video service providers, consumer electronics and set-top box manufacturers and interactive television software and program guide providers in the online, over-the-top video and mobile phone businesses.

The Product segment covers licensing of company-developed IPG products and services provided for multichannel video service providers and consumer electronics manufacturers, in-guide advertising revenue, analytics revenue and revenue from licensing metadata.

The massive $18 B. Riley FBR price target is still less than the $21.54 consensus target. Shares have traded recently below $7.

Five stocks for aggressive accounts looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, these are not penny stocks with absolutely no track record or liquidity, and major Wall Street firms have research coverage.